Peptides for Thyroid Disorders — Evidence Review
Thyroid disease is one of the few endocrine conditions with cheap, safe, and highly effective first-line therapy. Levothyroxine for hypothyroidism, methimazole or radioiodine for hyperthyroidism.…
Thyroid disease is one of the few endocrine conditions with cheap, safe, and highly effective first-line therapy. Levothyroxine for hypothyroidism, methimazole or radioiodine for hyperthyroidism. Hashimoto's and Graves' have an autoimmune component but standard care does not include peptide therapy.
This page exists because thyroid disease appears in the footer condition list and because patient forums sometimes discuss peptides for thyroid concerns. The honest review is short: peptide evidence here is thin.
Peptides with limited but plausible mechanistic case
Selank
Selank is an anxiolytic peptide that modulates GABA and HPA-axis activity. Some patients with hyperthyroidism experience anxiety as part of the symptom cluster; selank's anxiolytic action is mechanistically plausible for adjunctive symptom management. There are no thyroid-specific trials. This is symptom-targeted, not disease-modifying.
Thymosin Alpha-1
Has an immune-modulating profile relevant to autoimmune disease conceptually. Limited published data in autoimmune thyroid disease specifically. The strongest thymosin alpha-1 trials are in chronic hepatitis B and septic shock, not thyroid.
Full thymosin alpha-1 profile →
What the evidence does not support
- Any peptide as a substitute for levothyroxine in hypothyroidism
- Any peptide as a substitute for antithyroid medication in Graves' disease
- BPC-157, TB-500, or GHK-Cu for "thyroid healing" — there is no evidence these affect thyroid function or autoantibody titers
- GH secretagogues for thyroid concerns — these may interact with thyroid hormone metabolism (free T4 may decrease modestly with GH/IGF-1 elevation), making baseline-monitored hypothyroidism management less stable
Important interactions
If you are on thyroid replacement therapy and considering any peptide — particularly GH secretagogues (CJC-1295, ipamorelin, sermorelin, MK-677) — your free T4 and TSH should be monitored. GH/IGF-1 elevation can shift the deiodinase activity that converts T4 to T3, potentially altering apparent thyroid status on labs.
GLP-1 agonists (semaglutide, tirzepatide) have FDA boxed warnings for medullary thyroid carcinoma based on rodent C-cell tumor data. Patients with personal or family history of MTC or MEN2 syndrome should not use GLP-1 agonists.
Where to source
If a clinician approves a peptide trial alongside thyroid management, vendor selection matters:
- Selank vendor rankings — limited
- Thymosin Alpha-1 vendor rankings — limited
What we don't know
- Whether immune-modulating peptides affect Hashimoto's antibody titers or disease progression
- Whether MOTS-c or AMPK-activating peptides indirectly influence thyroid metabolism
- Long-term effects of GH-elevating peptides on thyroid hormone homeostasis
Methodology
Read the full methodology.
This page is educational. Thyroid disease management requires endocrinology or primary-care oversight with regular lab monitoring. Most patients on appropriate thyroid replacement do not need peptide therapy.